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The genomic sequences of low and high passages of the United States infectious laryngotracheitis (ILT)
vaccine strains CEO and TCO were determined using hybrid next generation sequencing in order to
deﬁne genomic changes associated with attenuation and reversion to virulence. Phylogenetic analysis
of available full genomes grouped strains into three major clades: TCO, CEO, and Australian.
Comparative genomics revealed that TCO attenuation is likely the result of an ORF C truncation. Genes
involved in attenuation are generally clade-speciﬁc, however four genes ORF C, UL27, UL28 and UL39
commonly contained various mutations across the CEO and TCO lineages. The Thr644 mutation in the
UL27 gene encoding glycoprotein B was identiﬁed in all virulent US strains. The US10 gene was
identiﬁed as a potential virulence factor for the TCO revertant 81658. The UL41 gene was responsible for
the robust gain in virulence of CEO-Fowl Laryngotracheitiss after 20 passages in chickens.
Published by Elsevier Inc.Introduction
Infectious laryngotracheitis (ILT) is a highly contagious respira-
tory disease of chickens caused by Gallid herpesvirus-1 (GaHV-1)
(Guy and Garcia, 2008), a member in the genus Iltovirus, of the
Alphaherpesvirinae subfamily within the family Herpesviridae
(Davison et al., 2005a). First described by May and Tittsler (1925),
the severe form of the disease is characterized by clinical signs
including, watery eyes, hemorrhagic conjunctivitis, nasal discharge,
respiratory rales, gasping, marked dyspnea, and expectoration of
blood-stained mucous. Morbidity and mortality can vary depending
on the viral strain, and the severe epizootic form of the disease can
cause morbidity up to 100% and mortality as high as 70% (Guy and
Bagust, 2003). Although it was the ﬁrst poultry pathogen controlled
by vaccination, ILT is still a major problem in areas where dense bird
populations exist (Bagust and Johnson, 1995). Over the last 40 years
the disease has largely been controlled through mass vaccination
with live attenuated strains derived from virulent US ﬁeld strains
circulating in the late 1950s and early 1960s (Guy and Garcia, 2008).
These isolates were attenuated through serial passage either inInc.
(S. Riblet),
patz).embryonated eggs (CEO) or in embryonic chicken cell cultures (TCO)
(Gelenczei and Marty, 1962; Samberg and Aronovici, 1969). There
are four commercially available CEO vaccines in the US. Three of
these vaccines, Trachivaxs, LT Blens and Fowl Laryngotracheitiss
originated from the Hudson strain, a virulent ﬁeld isolate that dates
back to Beaudette and Hudson (1933). The fourth is Laryngo-Vacs
which originated from the Cover strain (Cover and Benton, 1958).
Only one TCO product LT-Ivaxs is commercially available and
originated from a virulent ﬁeld strain isolated in the early 1950s
(Gelenczei and Marty, 1962).
In addition to their abilities to induce protective immunity and
prevent clinical signs and mortality (Fulton et al., 2000; Han and
Kim, 2003), all live attenuated GaHV-1 vaccines can persist in a
latent state in apparently healthy birds (Andreasen et al., 1989;
Hughes et al., 1989). Long-lived birds are therefore reservoirs of
vaccine viruses that can potentially be reactivated and contribute
to the spread of the disease (Andreasen et al., 1989; Hilbink et al.,
1987; Rodrı´guez-Avila et al., 2007). Live attenuated vaccines can
also easily transmit from vaccinated to unvaccinated birds, and
after sequential passages in birds they may regain virulence.
Recombinant viral vectored vaccines expressing GaHV-1 genes
encoding glycoproteins (e.g. fowlpox expressing glycoprotein B
and Melagrid herpesvirus expressing glycoproteins D and I) were
introduced in 2007 as safer GaHV-1 vaccine alternatives (Cochran
and MacDonald, 1998; Tong et al., 2001).
Table 1
Vaccine strains and ﬁeld isolates utilized in full genome comparisons.
Vaccines &
isolates
Viral DNA
sequencing
Origin Genotype Virulence
CEO
Trachivaxa
p1 CKc Trachivax LT#67/2008d IV 0g
CEO p1a p2 CK Fowl laryngotracheitis,
1991e
IV 0h
CEO p20a p2 CK Fowl laryngotracheitis,
1991 e
IV þþþh
63140b P2 CK Broiler isolate, GA.
2006
V þþþþi
LT-IVAXa p1 CK LT-IVAX Serial #89364/
2006d
II 0g
TCO p1a p2 CK LT-IVAX, 1991f II 0h
TCO p20a p2 CK LT-IVAX, 1991f II þh
81658b P2 CK Broiler-breeder isolate,
TX. 2010
III þþj
1874C5b P2 CK Broiler isolate VI þþþþk
USDAb Unknown Standard reference
strain
I þþþþi
a Genomes obtained in this study.
b Genomes obtained in Spatz et al. (2012).
c Passage in chicken kidney cells utilized for puriﬁcation of viral DNA.
d Merck Animal Health, Summit, NJ, U.S.A.
e Vaccine from Vineland Laboratories Vineland, NJ, passed once (p1), or 20
times (p20) in chickens, followed by plaque puriﬁcation in chicken
kidney cells.
f Vaccine from American Scientiﬁc Laboratories, Schering Corp., Cream Reach,
NJ, passed once (p1) and 20 consecutive times (p20) in chickens, followed by
plaque puriﬁcation in chicken kidney cells.
g Rodrı´guez-Avila et al., (2008).
h Guy et al. (1991).
i Vagnozzi et al. (2012).
j Non-published.
k Oldoni et al. (2009).
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do exist among the CEO and TCO vaccine strains. Rodrı´guez-Avila
et al. (2007) reported that the rates of replication and transmission
of the CEO vaccine strain are greater than those of the TCO vaccine.
Although both vaccine strains can regain virulence after bird-to-bird
passage, CEO revertants cause a more severe respiratory disease
with higher mortality rates, when compared to TCO revertants at
the same bird passage level (Brandly and Bushnell, 1934; Guy et al.,
1991). In spite of shortcomings associated with reversion to viru-
lence most US commercial layers and broiler breeders, particularly
those raised in locations with high exposure risk, are vaccinated
with either TCO vaccine applied by the eye-drop route or with CEO
vaccine applied in drinking water or by coarse spray. However,
broilers are vaccinated with CEO vaccines only in an imminent
outbreak (Davison et al., 2005b). Although vaccination with the live-
attenuated ILT vaccines has been widely utilized in breeders and
layers, severe and long-lasting outbreaks in broilers have been
frequently reported (Davison et al., 2005b).
Early molecular epidemiology studies involving restriction
endonuclease (R.E.) proﬁling have demonstrated that the majority
of the isolates associated with outbreaks in the US showed R.E.
banding patterns closely resembling those of digested CEO DNA,
while outbreaks related to TCO-like isolates were fairly rare (Guy
et al., 1989; Keeler et al., 1993; Keller et al., 1992). To date,
differentiation of vaccine strains from virulent ﬁeld isolates has
mainly involved restriction fragment length polymorphisms of
PCR products (multilocus PCR-RFLP analyses) (Creelan et al.,
2006; Kirkpatrick et al., 2006; Neff et al., 2008; Oldoni et al.,
2008) and limited nucleotide sequence analysis (Han and Kim,
2001; Neff et al., 2008). Using multi-locus PCR-RFLP analyses,
(Oldoni et al. (2008)) have reported that US isolates from
commercial and non-commercial poultry can be genotyped into
nine clades (I through IX). Over a decade (1997 to 2007), this
procedure grouped 68 commercial poultry outbreak-related iso-
lates into four genotypes (groups III, IV, V, and VI). Seventy six
percent (52/68) were genotyped as either similar to CEO vaccine
Group IV or the closely related Group V genotype. Only three
isolates were genotyped as closely related to the TCO vaccine
(Group III genotype). The remaining 19% (13/68) isolates appear
to be dissimilar to the CEO and TCO genotypes and belong to the
virulent group VI genotype (Oldoni and Garcia, 2007; Oldoni et al.,
2008). In a European study of isolates collected over 35 years, 94%
(98/104) of the isolates were also shown to be related to ILT
vaccine strains (Neff et al., 2008). Similarly, by determining the
nucleotide sequence of ICP4 amplicons, Sadeghi et al. (2011)
reported that Iranian GaHV-1 ﬁeld isolates were phylogenetically
indistinguishable from CEO vaccine strains. Based on these data, it
has been postulated that North American, European and Middle
Eastern CEO vaccine strains have reverted to virulence and that
these revertants have become established in the poultry popula-
tions (Ojkic et al., 2006).
The genomic changes that determine reversion to virulence and
attenuation of CEO- and TCO-related isolates are largely unknown
and full genome deep sequencing analysis of related strains may
provide some insight. Although DNA sequencing data from GaHV-1
has been publicly available since the late 1980s, the ﬁrst complete
genome was assembled by Thureen and Keeler (2006) from partial
genome sequences of different strains obtained in six laboratories
across the globe. Recently, non-composite full-length genome
sequences of the European CEO vaccine strain Serva (Lee et al.,
2011b), two Australian vaccine strains (A20 and SA2) (Lee et al.,
2011a), two Australian virulent strains CL9 and ACC78 (Lee et al.,
2012), two US CEO strains (LT Blens and Laryngo-Vacs) (Chandra
et al., 2012) and four virulent US isolates (Spatz et al., 2012) (USDA
reference challenge strain [Group I], broiler breeder isolates 81658
[Group III], 63140 [Group V] and 1874C5 [Group VI] were obtained.The objective of this study was to identify genomic changes
associated with reversion to virulence and attenuation of GaHV-1
live attenuated vaccines strains by comparing full genome
sequences of current CEO Trachivaxs and TCO LT-Ivaxs vaccines
(Merck Animal Health, Summit, N.J. USA) with chicken passages
1 and 20 of CEO Fowl Laryngotracheitiss and TCO vaccine LT-Ivaxs
performed in 1991 by Guy et al. (1991), as well as sequences of
known virulent US GaHV-1 isolates.Results and discussion
Origin of the virus isolates
Guy et al. (1991) conducted an experiment in which Fowl
Laryngotracheitiss (CEO) and LT-Ivaxs (TCO) vaccines were
passaged twenty consecutive times in chickens after initial
intra-tracheal inoculation. Following virus isolation and plaque
puriﬁcation, stocks of the 1st (p1) and 20th (p20) passages of the
CEO Fowl Laryngotracheitiss and the TCO LT-Ivaxs vaccines were
propagated in the chorioallantoic membrane of chicken embryos
and stored in the repository of Dr. Jim Guy at North Carolina State
University (Raleigh, N.C.). The origin, genotypes, and passage
history of vaccine strains and virulent isolates are presented in
Table 1. Since additional in vitro passages were required in order
to propagate enough viral DNA for sequencing, it is possible that
additional mutations could have arisen during limited in vitro
propagation. However, based on the dramatic changes in allele
frequencies in some cases a total reversion of allele frequency in
late passage was observed (see below), we believe the poly-
morphic bases identiﬁed in this report were present in the
plaque-puriﬁed populations. Similarly polymorphic bases have
been identiﬁed in plaque puriﬁed isolates of three strains of the
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allele frequency upon ten passages of one of these strains Becker
was reported by Szpara et al. (2011). To address this, future ILTV
studies will undoubtedly involve sequencing directly from tissues
of chicken infected with sequentially passed vaccine inoculums.
DNA statistics and genomic organization
In order to determine genes associated with attenuation/
virulence, this comparative genomics study has identiﬁed gross
mutations and polymorphic bases that differed among the newly
sequenced US vaccine strains (Trachivaxs, passages of Fowl
Laryngotracheitiss, LT-Ivaxs and passages of LT-Ivaxs) and
sequences of both virulent and vaccine strains currently depos-
ited within GenBank.
The nucleotide sequences of the GaHV-1 vaccines strains have
been submitted to GenBank and their accession numbers are as
follows: LT-Ivaxs (JN580312), LT-Ivaxs p1 (JN580315), LT-Ivaxs
p20 (JN580314), Trachivaxs (JN580313), Fowl Laryngotracheitiss
p1 (JN580317) and Fowl Laryngotracheitiss p20 (JN580316). The
DNA sequencing statistics with respect to the number of reads and
the fold coverage are presented in Table 2. On average there was a
37 fold coverage with the 454 data and a 5594 fold coverage using
Illumina data. Although the read lengths were considerably longer
(average 270 bp) using the 454 pyroseqeuncing technology, the
depth of coverage using the Illumina technology was over two logs
greater. The use of both technologies allowed for the accurate
resolution of homopolymer stretches (a shortcoming of 454 tech-
nology) and accurate de novo assembly of the genomes (a short-
coming of Illumina short read technology). The genome lengths (bp)
of the GaHV-1 isolates are as follows: 155,465 (LT-Ivaxs and
LT-Ivaxs p1); 150,335 (LT-Ivaxs p20); 153,647 (Trachivaxs and
Fowl Laryngotracheitiss p20); and 153, 641 (Fowl Laryngotrachei-
tiss p1). Unlike the class E-type genomic organization of the
prototype alphaherpesvirus herpes simplex virus-1 (HSV-1) with
inverted repeats bracketing both the unique long and unique short
regions, the GaHV-1 genomes are organized as class D-type with
inverted repeats ﬂanking only the unique short region. The unique
short regions of the two vaccine strains are identical in length
(13,094). However, the unique long regions differ by 3340 base pairs
(112,915 Trachivaxs vs 109,575 LT-Ivaxs). In order to investigate
these differences a multiple sequence alignment (Fig. 1) of
sequenced GaHV-1 genomes was generated using MAFFT (Katoh
et al., 2005). The differences in the lengths of the unique long
regions are attributed to 3337 bp deletions at the 50 end of the
genomes (Fig. 1B) and a three nucleotide deletion within the UL37
gene of LT-Ivax and its passages. This large 3.3 kb deletion was also
present within the genomes of the USDA and 81658, suggesting a
common lineage of these virulent strains with the TCO LT-Ivaxs
vaccine strains.
Sequence length differences in the repeat regions also vary
among the strains as well as between chicken passages (p1 andTable 2
Sequencing statistics.
Vaccines &
isolates
Total reads
454
Coverage Total reads
illumina
Coverage
CEO Trachivaxs 55,575 8 16,883,473 1,1582
CEO p1 30,935 18 3,539,234 2,428
CEO p20 20,179 19 11,444,063 8,014
63140 28,100 20 7,817,890 5,363
LT-IVAXs 89,321 139 6,210,920 4,284
TCO p1 35,446 47 9,096,173 6,339
TCO p20 8,117 9 1,367,246 980
81658 ND ND 8,370,909 5,759p20) of the TCO LT-Ivaxs vaccine. The inverted repeats of all
newly sequenced CEO genomes (Fig. 1C) are 13,819 bp in length,
similar to the 13,833 bp length of the high passage LT-Ivaxs (p20)
inverted repeats. Interestingly, LT-Ivaxs vaccine stock and
LT-Ivaxs p1 are signiﬁcantly longer (16,398 bp) due to the
presence of four copies of the 855 bp repeat within the hypervari-
able region (Fuchs et al., 2007) which is adjacent to the promoter
region of the ICP4 gene.
Differences in the ICP4 genes of CEO and TCO genomes were
identiﬁed through multiple sequence alignments. The genomes
CEO clade members contain a single copy of the sequence
gcggcccaagac (coordinates 145,200 to 145,211 in the USDA
reference genome) per inverted repeat. Two tandem copies of
this sequence are found within the ICP4 genes of TCO members.
The signiﬁcance of this duplication is unknown but may be useful
in diagnostic assays.Phylogenetic analysis
The phylogenetic relationship among the newly sequenced
genomes of US vaccine strains CEO (Trachivaxs and Fowl Laryngo-
tracheitiss p1) and TCO (LT-Ivaxs), US virulent strains (63140,
81658, 1874C5, USDA reference), US CEO strains Laryngo-Vacs and
LT Blens, the European strain Serva, and Australian vaccine strains
(SA2 and A20) and Australian virulent strains CL9 and ACC78 are
depicted in Fig. 2. The evolutionary tree grouped the available
GaHV-1 nucleotide sequences into four major clades (CEO, TCO,
group V and AU) and suggests that the US vaccine strain TCO LT-
Ivaxs and CEO Trachivaxs/Fowl Laryngotracheitiss form distinct
evolutionary groups. Notably this tree is in agreement with the
dendrogram that partitioned the US GaHV-1 isolates into nine
genotypes based on cluster analysis of PCR-RFLP patterns (Oldoni
and Garcia, 2007).
The CEO clade (in bold Fig. 2) includes the US CEO vaccine strains
LT Blens, Trachivaxs, Laryngo-Vacs, Fowl Laryngotracheitiss, the
US virulent group V strain 63,140, the European Serva vaccine and
the virulent Australian natural recombinant ACC78. Interestingly,
CEO clade members from the US mainly originated from the Hudson
strain (Beaudette and Hudson, 1933). These include Trachivaxs,
Fowl Laryngotracheitiss and LT Blens. Only one (Laryngo-Vacs)
originated from the Cover strain. Based on the phylogenetic group-
ing and the timeline of isolation, the Cover strain (circa 1958) most
likely originated from the Hudson strain (circa 1933).
The TCO clade includes the virulent USDA reference strain and
strain 81658 which was isolated from a breeder ﬂock where TCO-
vaccinated males were mixed with non-vaccinated birds. This
may suggest that strain 81658 is a vaccinal revertant. The
phylogenetic tree also suggests that TCO strains either originated
from the USDA reference strain or from a common ancestor.
Notably both the USDA and 81658 strains contain the signature
3.3 kb deletion at the 50 ends of their genomes (Fig. 2C).
The Australian vaccine strains (SA2 and A20) and Australian
virulent strain CL9 are distantly related to the other GaHV-1
strains, as is 1874C5 strain, and forms the new Australian (AU)
clade. Most interestingly is the placement of virulent Australian
strains ACC78 outside of the Australian clade and within the CEO
clade. Similarity plots (Lee et al., 2012) of the sequences of ACC78
and CL9 genomes with those of Serva, A20, and SA2 indicate that
both genomes contain sequences derived from the Serva gen-
omes. These plots also suggest virulent CL9 contain sequences
derived from A20 and these sequences are largely responsible for
its placement within the Australian clade. The placement of
virulent ACC78 within the CEO clade is due to shared sequences
with the Serva strain. Because similarity plots could not deﬁned
whether ACC78 originated from SA2 or A20 – the recombinant
Fig. 1. The genomic location of the major deletions at the termini of the Gallid herpesvirus 1 genomes. (A) The typical GaHV-1 genome with the unique long (UL) and unique
short (US) which is surrounded by repeat regions; internal repeat short (IRS) and terminal repeat short (TRS). Black arrows represent selected ORFs and grey boxes denote
origins of replication. Two regions at the termini of the GaHV-1 genomes containing gross genetic alterations were enlarged. (B) The termini of GaHV-1 strains USDA,
81648, LT-Ivaxs, LT-Ivaxs p1 and LT-Ivaxs p20 (TCO clade members) showing the 3337 bp deletion at the 50 termini and multiple copies (white arrows) of the 855 bp in
the hypervariable region within the promoter of ICP4. The names of the virulent strains are in bold and underlined. (C) The termini of GaHV-1 strains 63140, Trachivax,
Fowl Laryngotracheitiss p1, Fowl Laryngotracheitiss p20, Serva, Laryngo-Vac and LT-Blen (CEO clade members) showing the single copy (white arrows) of the 855 bp in
the hypervariable region within the promoter of ICP4. (D) The termini of GaHV-1 strains of Australian strains ACC78, CL9, A20 and SA2; and US strain 1874C5 showing the
50 termini containing insertions (a–h) and single copy (white arrows) of the 855 bp in the hypervariable region within the promoter of ICP4. The lengths and map
coordinates for the insertions are as follows: a, 100 bp, 3263–3362; b, 193 bp, 3283–3475; c, 192 bp, 3283–3474; d, 20 bp, 3554–3573; e, 20 bp, 3667–3686; f, 20 bp, 3666–
3685; g, 33 bp, 4655–4687; h, 33 bp, 4654–4686.
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virulent component is unknown at this time.
Virulent versus vaccine
In the composite genome generated by Thureen and Keeler (2006)
80 ORFs were annotated based on similarities to the translation
products of other herpesviruses genes. When comparing the genomes
of the US CEO and TCO clade isolates, deletions were identiﬁed in
only three genes (ORF C, UL37 and ICP4). These deletions were all inframe and are unlikely to affect the protein’s function. In contrast a
point mutation was identiﬁed in the ORF C genes of some members
of the TCO clade. This Iltovirus speciﬁc gene encodes a polypeptide of
334 amino acids with two protein products (30 and 38 kDa) as
detected on Western Blots (Veits et al., 2003). This 334 amino acids
protein is predicted for the ORF C genes of US GaHV-1 virulent
isolates 63140, 1874C5, US CEO vaccine strains (Trachivaxs, Fowl
Laryngotracheitiss p1, Fowl Laryngotracheitiss p20, LT Blens,
Laryngo-Vacs) and European CEO Serva vaccine strain. However,
due to a C-T mutation that introduces a TAA (ochre) stop codon, a
Fig. 2. Dendogram of 12 Gallid herpesvirus 1 strains. The tree was generated from a
multiple alignment of whole genome sequences (unique long, internal repeat
short and unique short) using the web-based MAFFT program. The tree was drawn
using Tree Explorer of the phylogenetic and molecular evolutionary program
MEGA version 4.0.2. The phylogenetic tree was constructed using complete
genomes from GenBank for 81658 (JN542535), 1874C5 (JN542533) 63140/C/08/
BR (JN542536) USDA reference strain (JN542534), SA2 (JN596962), A20
(JN596963), Laryngo-Vacs (JQ083494) LT-Blens (JQ083493), Serva (HQ630064),
CL9 (JN804827), ACC78 (JN804826) and genome sequences generated in this study
for LT-Ivaxs (JN580312), Trachivaxs (JN580313), and Fowl Laryngotracheitiss
(JN580317). Members of the CEO clade are in bold. Members of the TCO clade are
italicized and underlined.
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all TCO genomes sequenced (LT-Ivaxs, LT-Ivaxsp1, LT-Ivaxsp20).
Interestingly this truncated protein was also predicted in the ORFC
gene of virulent isolate 81658, a strain that originated from a ﬂock
experiencing severe ILT clinical signs after the introduction of cocks
vaccinated with the LT-Ivaxs vaccine. Preliminary data indicate that
strain 81658 showed moderate virulence in experimentally infected
broilers (data not shown).
Although both the LT-Ivaxs and 81658 genomes contain the
common mutation responsible for the ORF C truncation, minor
differences do exist between the genomes of 81658 and LT-Ivaxs
p1. Only ﬁve nucleotides differed between the genomes of LT-
Ivaxs p1 and that of the virulent 81658 isolate. Speciﬁcally an
intergenic T/G mutation mapped between the 30 ends of UL40 and
UL41 at nucleotide positions 68,481 for both LT-Ivax
s and 81658,
respectively. Of the four intragenic mutations identiﬁed two
mapped within the unique long region and two within the repeat
short region. A synonymous mutation (C/T at position 60,957)
mapped within the UL37 gene. Perhaps of more signiﬁcance a T/C
substitution at position 109,115 was identiﬁed within the intron
of Iltovirus-speciﬁc gene UL-1. Only one non-synonymous muta-
tion Met136Ile was identiﬁed which mapped within the diploid
US10 genes (Iso136 in 81648) at positions 124,169/121,604 (G/A)
and 140,872/138,307 (C/T) for LT-Ivaxs and 81658, respectively.
These US10 mutations (ATA codon) were unique to the virulent
81658 isolate and not found in other TCO clade members. All
other published GaHV-1 genomes contain the ATG (Met) codon at
this position. Little is known of the function of the US10 gene in
GaHV-1. This annotated US10 homologue has very low sequence
identities at the amino acid level (31.3%, 29.8%, 28.6% and 28.4%)
to known US10 homologues of other avian herpesviruses (GaHV-
3, GaHV-2, DHV-1 and MeHV-1, respectively). Interestingly, in
GaHV-1 the US10 gene product has been demonstrated to interact
with SCA2, a member of lymphostromal cell membrane Ly-6superfamily, which is involved in T cell differentiation and
activation (Liu et al., 2003).
Besides these differences both the LT-Ivaxs and virulent
81658 genomes contain identical deletions at their 50 termini
(3337 bp after nucleotide 2153; Fig. 1). Furthermore both LT-
Ivaxs p20 and 81658 contained a single copy of the 855 bp repeat
element per inverted repeat, unlike the 4 copies/inverted repeat
found in the genomes of LT-Ivaxs p1 and LT-Ivaxs vaccine stock.
Notably, LT-Ivaxs p20 and the virulent strains USDA and 81658,
contained fewer copies of the 855 bp repeat then their attenuated
counterparts. This may indicate that expansion of this region
attenuates the virus perhaps in a fashion similar to the attenuat-
ing expansion observed in the 132 bp repeat region within the
genome of Marek’s disease virus (Ross et al., 1989; Silva and
Witter, 1985). Although it may be attractive to suggest that
virulence of TCO members could be related to the loss of the
number of 855 bp repeats, other vaccine strains outside the TCO
clade (Serva, SA2 and A20) contain only a single copy of the 855
repeat element. It is largely suspected that the Ile136 non-
synonymous mutation in US10, which is exclusively found in
the 81658 genome is responsible for its virulent phenotype.
Because the 81658 genome is 99.99% identical to that of LT-
Ivaxs and given the similarities mentioned above, it is highly
likely that 81658 is a TCO revertant.
If strain 81658 is likely a TCO revertant perhaps virulent strain
63140 is a CEO revertant? Phylogenetically, 63140 partitioned
with the US CEO vaccine strains and the European Serva strain
(Fig. 2), indicating a common lineage. Furthermore, strain 63140
was isolated from a non-vaccinated broiler ﬂock located in
northeast Georgia, US, a region with a long history of ILT out-
breaks that are frequently controlled using CEO vaccinations. To
address this question, the genome of 63140 was compared to the
genome of all CEO clade members. In particular, a comparison
between 63140 and CEO Fowl Laryngotracheitiss p1 revealed 40
base pair changes. Of these, 20 mutations within 17 genes (ORF C,
ORF E, ORF F, ICP4, UL5, UL10, UL17, UL23, UL26, UL27, UL28, UL36,
UL38, UL39, UL54, US5 and US8) were identiﬁed as intragenic
(Table 3). However, the SNPs (codons in bold Table 3) found in the
genes ICP4, UL54, UL5, UL38 and US8 within the 63140 genome
were also found in the genomes of other CEO vaccine strains.
Discarding mutations found in these ﬁve genes, the remaining 12
genes may likely encode potential virulence factors. Based on the
phylogenetic partitioning of the 63140 genome along the CEO
branch and the relatively low number of mutations that were
exclusive to the 63140 genome, it is postulated that 63140
evolved from CEO-like strains that circulated in the ﬁeld.
The virulent reference strain USDA partitioned along with TCO
vaccine LT-Ivaxs and virulent 81658 strains. The genome of this
reference strain differs from LT-Ivaxs p1 by 111 SNPs and contains
21 non-synonymous mutations distributed in 12 genes (ORF C, UL0,
UL-1, UL5, UL27, UL28, UL29, UL37, UL39, UL46, UL47 and ICP4
(Table 4). However, the GCA codon encoding Ala391 within the
UL5 genes of the USDA strain is also in the genomes of LT-Ivax
s p20
and LT-Ivaxs vaccine stock. Discarding this gene the list is reduced
to 11 genes that are likely to encode virulence factors.
The US strain 1874C5 was phlylogenetically distinct from all
other US strains. Twenty exclusive SNPs (Supplement Table 1) the
majority of which were in two genes, UL30 and ICP4 were
catalogued. Because of its unique partitioning and the fact that
all other sequenced virulent strains are phylogenetically related
to vaccine strains, 1874C5 is unlikely to be a vaccinal revertant.
A difﬁcult aspect in the identiﬁcation of mutations related to
virulence is the lack of a consensus found among all virulent
isolates (USDA, 63140, 81658 and 1874C5). Mutations seem to be
genome speciﬁc and most often fail to group among similar
strain’s pathotypes. A comparison between the virulent genes
Table 3
Genes containing non-synonymous mutations that differ among vaccine strain CEO p1 and virulent isolate 63140.
Gene AA change AA position Trachivax CEO p1 CEO p20 63140 Laryngo-Vac LT-Blen Serva
1 ORF C del-Asp 67 – – – gat – – –
2 ORF E Gly-Ala 133 ggc ggc Ggc gcc ggc ggc ggc
3 ORF F Thr-Ser 78 tca tac Tca aca tca tca tca
4 ICP4 Ala-Thr 1152 act gct gct act act act act
5 UL54 Met-Ile 479 atg atg atg ata ata atg ata
6 UL23 Arg-Trp 97 cgg cgg cgg tgg cgg cgg cgg
7 UL39 Asp-Asn 20 gac gac gac aac gac gac gac
8 UL36 Ser-Gly 359 agc agc agc ggc agc agc agc
9 Arg-His 1347 cgc cgc cgc cac cgc cgc cgc
10 UL5 Lys-Glu 343 aaa aaa gaa gaa aaa aaa aaa
11 UL26 Gln-Arg 179 cag cag cag cgg cag cag cag
12 UL38 Val-Ala 290 gcc gtc gcc gcc gcc gcc gcc
13 UL28 Asp-Gly 735 gac gac gac ggc gac gac gac
14 UL17 Ala-Thr 320 gca gca gca aca gca gca gca
15 UL27 Arg-His 496 cgc cgc cgc cac cgc cgc cgc
16 Ile-Thr 644 ata ata ata aca ata ata ata
17 Glu-del 809 gag gag gag – gag gag gag
18 UL10 Thr-Ala 42 acc acc acc gcc acc acc acc
19 US5 Ala-Thr 340 gcc gcc gcc acc gcc gcc gcc
20 US8 Lys-Arg 210 aaa aaa aaa aga aga aaa aaa
Codons in bold are there for clarity.
Table 4
Genes containing non-synonymous mutations that differ between TCO p1 and
virulent USDA reference strain.
Gene AA
change
AA
position
LT-
Ivax
TCO p1 TCO
p20
USDA 81658
1 ORF C Gln–Stop 304 taa taa taa caa taa
2 UL0 Pro–Ser 153 cca cca cca tca cca
3 Thr–Ala 378 aca aca aca gca aca
4 UL(-1) Ala–Val 252 gca gca gca gta gca
5 ICP4 Ala-Pro 199 gcc gcc gcc ccc gcc
6 Asp–Asn 747 aac aac aac gac aac
7 Asp-Gly 1333 gac gac gac ggc gac
8 UL39 Gly-Cys 263 ggc ggc ggc tgc ggc
9 Ala-Thr 349 gca gca gca aca gca
10 Ser-Gly 530 agc agc agc ggc agc
11 UL29 Asp-Gly 905 gac gac gac ggc gac
12 UL5 Ala-Thr 391 gca aca gca gca aca
13 UL37 Del-Leu 462 – – – cta –
14 Ile-Met 667 ata ata ata atg ata
15 UL28 Glu–Gly 363 gaa gaa gaa gga gaa
16 Arg-Gln 374 cga cga cga caa cga
17 Ile–Thr 509 att att att act att
18 UL46 Asp-Tyr 327 gac gac gac tac gac
19 sORF1 Asp-Gly 279 gac gac gac ggc gac
20 UL27 Thr-Met 348 acg acg acg atg acg
21 Ile-Thr 44 ata ata ata aca ata
Codons in bold are there for clarity.
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UL39, UL28 and ICP4) that are common to both lists. Little is
known about the role of the ORF C protein in GaHV-1 virulence.
The helicase protein encoded by UL5 has been identiﬁed as a
virulence factor in HSV-1 by Biswas et al. (2008, 2009). By
investigating resistance to helicase-primase inhibitors they dis-
covered that mutants containing an Asn342Lys substitution grew
slower with a moderate reduction in virulence compared to wild
type. Strikingly, we have identiﬁed a Glu343Lys polymorphism
between vaccine and virulent members of the CEO clade. It is
postulated that Lys343 in the critical motif IV domain of UL5 is an
attenuating mutation and affects the viral DNA replication in CEO
vaccine strains.
It was not surprising that mutations in the genes encoding
glycoproteins (e.g. gB, gM, gJ and gE) were identiﬁed in this study
since they are involved in binding of the virus to susceptible cells.However it was interesting that the gene most conserved among
herpesviruses, UL27 encoding glycoprotein B, contained a rela-
tively large number of mutations. Four mutations (Arg496His,
Ile644Thr, Met348Thr and DGlu809 were identiﬁed in the glyco-
protein B genes. Interestingly the Thr644 mutation was found in
all virulent strains of GaHV-1 including the newly sequenced
Australian virulent isolates CL9 and ACC78 (Lee et al., 2012).
Mutations in the genes encoding gB homologues of other herpes-
viruses have been reported (Goodman and Engel, 1991;
Hutchinson et al., 1993) especially those involved in the syncytial
(syn) phenotype and many strains of HSV-1 attribute their
differences in virulence to mutations found in this gene. These
differences likely affect receptor binding and immunogenicity
since gB is a class III fusogen and major immunogen (Atanasiu
et al., 2010).
Glycoproteins M, J and E encoded by the UL10, US5 and US8
genes, respectively have also been implicated in virulence
(Kaashoek et al., 1994; van Engelenburg et al., 1994; Zhang
et al., 2009). Both gM and gE are essential for virus growth of
GaHV-2 in cell cultures as reported by Tischer et al. (2002);
however in GaHV-1 and in other alp will haherpesviruses (e.g
HSV-1, PRV, BHV-1, EHV-1 and EHV-4), gM is inessential for lytic
replication (Baines and Roizman, 1991; Fuchs and Mettenleiter,
1999; Kawabata et al., 2012; Konig et al., 2002; May et al., 2005).
In GaHV-1 and GaHV-2, glycoprotein E in conjunction with
glycoprotein I were found to be essential for growth in cultured
cells (Devlin et al., 2006; Schumacher et al., 2001). However
mutants containing deletions in gE have be described for vaccine
strains of pseudorabies (e.g. Bartha) and vaccine strains of bovine
herpesvirus 1 containing DgE deletions have been engineered by
Lomniczi et al. (1984), Mettenleiter et al. (1985), Szpara et al.
(2011), van Engelenburg et al. (1994)). Mundt have reported that
Glycoprotein J of GaHV-1 has been reported to be inessential for
lytic replication of GaHV-1 (Mundt et al., 2011) and recently DgJ
mutants have been demonstrated to be attenuated and safe for in
ovo inoculations to vaccinate against laryngotracheitis (unpub-
lished results).
The large subunit of ribonucleotide reductase encoded by UL39
has been reported to be a virulence factor of HSV-1, VZV (Brandt
et al., 1991; Cameron et al., 1988; Heineman and Cohen, 1994)
and GaHV-2 (Lucy Lee, personal communication). It is also within
reason that mutations in the terminase protein UL28 and the
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since these proteins are involved in packaging/cleavage of the
virus genome and activation of early/late gene expression, respec-
tively (Yang and Baines, 2006; Yu and Weller, 1998). Notably
some mutations (Thr509 and Asp742 within the UL28 and ICP4
genes, respectively) have been identiﬁed in both the virulent
1874C5 and the USDA reference strains.Sequence polymorphisms: Allele frequency
Two sequencing technologies were used to determine the
genomic sequences presented in this paper. While the longer
reads of 454 assisted initial assembly, the depth of coverage
(45000 fold) obtained by Illumina sequencing allowed for the
identiﬁcation of rare polymorphic bases in 8 genes (UL37, UL38,
UL41, UL5 ICP4, US10, US5 and US8) out of 80 ORFs examined
within the Trachivaxs, LT-Ivaxs and Fowl Laryngotracheitiss
passage populations and the frequencies in which they occurred.
Fluctuations in the allele frequencies were also identiﬁed at the
origin of replication (OriS) and in microRNA ICP4:iltv-miR-16-3p
within the ICP4 ORF. Similarly, Chandra et al. (2012) described
mixed genome populations within vaccine preparations of
Laryngo-Vacs and LT Blen.s
In this study we found that the Trachivaxs and LT-Ivaxs
vaccines also contained mixed genome populations, but different
genes were identiﬁed (UL38, ICP4, US5 and US8 of CEO Trachivax
sTable 5
Relevant allele frequencies for non-synonymous AA substitutions for Trachivax,
LT-Ivax and passages in chickens of CEO (Fowl laryngotracheitis) and TCO
(LT-Ivax) vaccines.
Isolate Gene Position Allele 1 Allele 2 AA1 AA2 Allele 1f Allele 2f
Trachivax UL38 290 gtc gcc Val Ala 14.52 85.48
LT-Ivax 0.06 99.94
CEO p1 99.83 0.17
CEO p20 0.04 99.96
TCO p1 0.08 99.92
TCO p20 0.00 100.00
Trachivax UL41 270 aca ata Thr Ile 99.97 0.03
LT-Ivax 99.94 0.06
CEO p1 99.95 0.05
CEO p20 4.97 95.30
TCO p1 100.00 0.00
TCO p20 99.87 0.130
Trachivax UL5 391 gca aca Ala Thr 99.97 0.03
LT-Ivax 60.10 39.90
CEO p1 99.95 0.05
CEO p20 99.95 0.05
TCO p1 0.08 99.92
TCO p20 97.83 2.17
Trachivax ICP4 1152 act gct Ala Thr 40.90 59.10
LT-Ivax 0.00 100
CEO p1 99.75 0.25
CEO p20 99.87 0.13
TCO p1 0.08 99.92
TCO p20 0.00 100
Trachivax US10 136 atg ata Met Ile 99.99 0.01
LT-Ivax 75.34 24.66
CEO p1 0.15 99.98
CEO p20 0.02 100.00
TCO p1 63.85 36.15
TCO p20 99.50 0.50
Trachivax US8 210 aaa aga Lys Arg 55.88 44.12
LT-Ivax 0.06 99.94
CEO p1 99.95 0.05
CEO p20 99.79 0.21
TCO p1 0.00 100
TCO p20 0.00 100and UL37, UL5 and US10 of TCO LT-Ivax
s) with grossly varying
allele frequencies in each of the vaccine populations. Most of the
codons that varied within a population encoded non-synonymous
amino acid substitutions (Table 5). Only two genes UL37 in TCO
populations (LT-Ivax, LT-Ivaxs p1 and LT-Ivaxs p20) and US5 in
passage populations of Fowl Laryngotracheitiss (CEO) contained
codons encoding synonymous substitutions for glutamine and
isoleucine, respectively (data not shown).Low and high passage comparisons
Deep sequencing analysis showed that ﬂuctuations in allele
frequencies also occurred during passage in chickens. When the
genomes of CEO Fowl Laryngotracheitiss p1 and p20 were
analyzed only 6 differences were identiﬁed. The intragenic differ-
ences were synonymous substitutions of Iso259 in US5 encoding
glycoprotein J, and two non-synonymous substitutions, Val290Ala
in UL38 and The270Ile in UL41. Intergenic mutations were
identiﬁed mainly in homopolymers of guanine within the pro-
moters of UL-1, US10 and ICP4. Polymorphic (A/G) bases within
the ‘‘back to back’’ promoters of ICP4 and US10 (position 121,465
the genomes of CEO Fowl Laryngotracheitiss p1) and a cytosine
homopolymer length difference at the 30 termini of Sorf4/3 and
US10 were also identiﬁed. Unlike passages of Fowl Laryngotra-
cheitiss (CEO), no intergenic mutations were found between
passages of TCO LT-Ivaxs. The contributions of these types of
mutations in virulence acquisition are difﬁcult to assess in silico,
but since they mainly occur in homopolymers it is likely that they
do not play a signiﬁcant role in virulence.
Of greater signiﬁcance and interest were the dramatic changes
in the allele frequencies within two genes (UL38 and UL41) in
passage populations of CEO Fowl Laryngotracheitiss. By passage
20 a near total reversal of allele frequencies was noted for the non
synonymous mutations in UL38 and UL41 (Table 5). The predo-
minate codon (99.95%) encoding Thr270 in UL41 of the CEO Fowl
Laryngotracheitiss p1 population was only present in 4.97% of
the population by passage 20. It is hypothesized that the Ile270
mutation in UL41 (present in 95% of the p20 populations) is
responsible for the robust gain in virulence following passage as
reported by Guy et al. (1991). UL41 encodes a ribonuclease
commonly referred to as virus host shutoff (vhs) and we postulate
that this mutation increases the activity of the vhs protein so that
stimuli (e.g. dsRNA) for nonspeciﬁc host defense mechanisms
(interferon production) are curtailed. It has been reported that
HSV-1 mutants containing a deletion in the UL41 gene are 5–20
fold more sensitive to interferon alpha and beta compared to the
wild type strain, respectively (Suzutani et al., 2000). It is less
likely that the dominate Ala290 mutation in UL38 within p20
populations contributes to virulence since this mutation is also
found in Trachivaxs populations at a high frequency (85.5%).
The passage-associated gain in virulence of Fowl Laryngotra-
cheitiss CEO strains are in stark contrast with those results
observed with passages of the TCO vaccine LT-Ivaxs in which
conversion to virulence occurred at a much lower frequency;
concurrently with the loss of three copies of the 855 base pair
repeat per inverted repeat region and some changes in allele
frequencies (Table 5). Even though the codons for Ala391 in UL5
and Met136 in US10 were present in greater proportions in LT-
Ivaxs p20 populations, their contribution to virulence is doubtful
due to the high proportion (60.10%) of the Ala391 codon in the
UL5 gene within the genome of LT-Ivax vaccine, and the high
proportions of the codon for Met136 in US10 found in both
passages (LT-Ivaxs p1 and LT-Ivaxs p20) (63.85% vs 99.5%).
Furthermore, given that the Ile136 mutation in US10 was the
only mutation that differentiated virulent 81658 from LT-Ivaxs
M. Garcı´a et al. / Virology 440 (2013) 64–74 71p1 it is unlikely that the Met136 mutation plays a role in
virulence.Genetic differences and pathogenicity of the GaHV-1 strains and
passages
During peer-review of this manuscript (Lee et al., 2012)
provided convincing evidence that a virulent class 9 ﬁeld virus
(CL9) resulted from natural recombination of attenuated vaccine
strains of Australian-origin (A20) and the European-origin Serva.
To investigate the likelihood that U.S. virulent strains 63140 and
81658 resulted from a recombination event involving either LT-
Ivaxs, Fowl Laryngotracheitiss or Trachivaxs whole-genome
multiple alignments were generated in MAFFT Katoh et al.
(2005) and used to produce similarity plots (data not shown)
based on the methods of Lole et al. (1999). Positions containing
gaps were stripped from the multiple alignment and percent
identity was calculated over 6000 base pair sliding window with a
step size of 20. Plots were generated from the resulting tables
using R (Team, 2009). These plots show that the 63140 and 81658
are more closely related to CEO and TCO strains, respectively than
those compared in the (Lee et al., 2012) paper, and there is no
obvious recombination events based on visual assessment. This
suggests that virulent strains 63,140 and 81658 arose through a
mechanism other than homologous recombination between vac-
cine strains of CEO and TCO.Fig. 3. Summary of amino acid changes among the TCO clade members USDA,
81658, LT-Ivaxs, LT-Ivaxs p1 and LT-Ivaxs p20 involved in virulence/attenuation
phenotypes. Arrows indicate the direction of the amino acid change for the
phenotypes. The boxes indicate genes containing non-synonymous substitutions
(corresponding to AA in bold in Table 4) that are found in the genomes of other
GaHV-1 strains within the clade.Summaries of the genes implicated in virulence/attenuation of
TCO and CEO clade members based on our comparative genomic
study are presented in Figs. 3 and 4. Overall few mutations were
found in common among the two distinct lineages of ILT vaccines.
Furthermore as reported in the study by Guy et al. (1991), gross
differences in their phenotypes upon serial passages in birds
suggest multiple genes are involved in reversion to virulence.
High passage of TCO vaccine LT-Ivax resulted in only moderate
gains in virulence. Genomic differences between plaque puriﬁed
passages of LT-Ivax were identiﬁed only in the region containing
the 855 bp repeats (Fig. 1). This correlation between virulence and
the reductions in the number of copies of the 855 bp repeats
appears to be TCO clade speciﬁc since single copies per inverted
repeat were also identiﬁed in CEO clade members. Reversion to
virulence of a TCO vaccine strain may involve (i) deletions in the
855 bp repeats to o2 copies per inverted repeats as seen with the
virulent USDA TCO strain, (ii) the repair of the ORF C truncation
and (iii) introduction of 21 mutations in 12 genes. Virulent strain
81658 appears to be a vaccinal revertant due to the isoleucine136
mutation within the US10, in spite of its retention of the ORF C
truncation (Fig. 3).
Minor sequence differences were identiﬁed between the two
Hudson strain derivatives Trachivaxs and Fowl Laryngotracheitiss
used in this study. They include a synonymous mutation for
Gly212 in the UL-1 gene and two non-synonymous mutations:
Ala290Val in UL38 and Thr1152Ala in ICP4 (Fig. 4). In comparing
passages of plaque-puriﬁed Fowl Laryngotracheitiss rapid acquisi-
tion of virulence after 20 passages in birds is likely due to the
Ile270 mutation in the virus host shutoff (vhs) protein encoded by
UL41 and probably does not involve the Ala290 mutation in UL38
since this mutation is also found in the CEO vaccine strain
Trachivaxs and virulent strain 63140. CEO member strain 63140
is virulent because of 20 single nucleotide polymorphisms dis-
tributed in 17 genes.Conclusions
Phylogenetic analysis indicates that CEO strains Trachivaxs,
Fowl Laryngotracheitiss, LT Blens, Laryngo-Vacs and the Eur-
opean Serva are part of a clade that include the virulent strain
63140. Mutations in 12 genes (ORF C, ORF E, ORF F, US5 UL17,
UL23, UL26, UL27, UL28, UL36, UL39 and UL10) were identiﬁed that
were exclusively found within the genome of virulent 63140
relative to the genomes of all other CEO genomes. One additional
gene UL41 is likely to encode the virulence factor responsible for
the rapid gain in virulence upon passage of the CEO strain Fowl
Laryngotracheitiss in birds.
The TCO strain LT-Ivaxs partitioned with the virulent strains
81658 and USDA reference and formed a unique clade distinct
from the CEO clade. A mutation in ORF-C resulting in a predicted
truncated polypeptide, was identiﬁed in vaccine strain LT-Ivaxs.
Five mutations were identiﬁed that differed among the genomes
of LT-Ivaxs and 81658; one of these (US10) is likely involved in its
virulence. Mutations in 11 genes (ORF C, UL0, UL-1, UL27, UL28,
UL29, UL37, UL39, UL46, UL47 and ICP4) were exclusive for the
USDA genome. No non-synonymous mutations exclusive for
higher passages of TCO LT-Ivaxs were identiﬁed. Moderate gains
in virulence of higher passages of TCO LT-Ivaxs are likely to
involve deletions in the copy number of the 855 bp repeat within
the ICP4 promoter.
In comparing the GaHV-1 genomes of virulent (63140, 81658, and
USDA) and vaccine strains (Trachivaxs, Fowl Laryngotracheitiss, LT
Blens, Laryngo-Vacs, Serva, SA2 and A20) mutations associated with
attenuation/virulence were identiﬁed in four genes encoding the Ilto
virus speciﬁc gene ORF C of unknown function, glycoprotein B
Fig. 4. Summary of amino acid changes among the CEO clade members 63140, Trachivax, Fowl Laryngotracheitiss p1 and Fowl Laryngotracheitiss p20 involved in
virulence/attenuation phenotypes. Arrows indicate the direction of the amino acid change. The boxes indicate genes containing non-synonymous substitutions
(corresponding to AA in bold in Table 3) that are found in the genomes of other GaHV-1 strains within the clade.
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ribonucleotide reductase encoded by UL39.Material and methods
Virus and cells
The GaHV-1 viruses utilized in this study were the chicken
embryo origin (CEO) vaccine Trachivaxs and Fowl Laryngotra-
cheitiss, and the tissue culture origin (TCO) vaccine LT-Ivaxs
(Merck Animal Health, Summit, N.J. US). In order to isolate viral
DNA, all viruses listed in Table 1 were propagated on conﬂuent
monolayers of chicken kidney (CK) cells using a MOI of 0.1 as
described previously by Tripathy and Garcia (2008). The micro-
coccal nuclease/polyethylene glycol procedure (Volkening and
Spatz, 2009) was used to isolate nucleocapsid DNA from the
isolates listed in Table 1.
High-throughput DNA sequencing
Sequencing of the GaHV-1 vaccine genomes was accomplished
using two sequencing technologies: 454 pyrosequencing and Illu-
mina sequence-by-synthesis. Initially sequencing was performed on
the Genome Sequencer 20 (GS20) system (454 Life Sciences) at the
Georgia Genomics Facility (University of Georgia, Athens, GA) was
used. To overcome limitations in 454 pyrosequencing related to
homopolymer resolution and to ﬁll remaining coverage gaps, all
vaccine strains and the group III isolate 81658 were re-sequencedusing the Illumina HiSeq 2000 sequencing platform running HCS
v1.4.8 (Illumina Inc., San Diego, CA) at the Genome Services Lab at
HudsonAlpha Institute for Biotechnology (Huntsville, Alabama).
For the initial 454 pyrosequencing, random libraries were con-
structed using 5.0 mg of nucleocapsid-puriﬁed DNA according to the
methodology as described by Margulies et al. (2005). Single read
genomic DNA libraries for Illumina sequencing were prepared from
5 mg of nucleocapsid puriﬁed genomic DNA that was fragmented by
sonication to an average length of 200 bp. The samples were
processed and indexed according to Illumina Library Creation kit’s
instructions, clustered on a cBot v1.4.36.0 using Illumina’sTruSeq PE
Cluster Kit v2.0 and sequenced on one ﬂowcell lane using a 200
cycle TruSeq SBS HS v2 kit. The clustered ﬂow-cell was sequenced
for 206 cycles, broken down into 3 separate reads. The ﬁrst read was
100 cycles in length, followed by a six-cycle index read. Following
the index read, paired end re-synthesis was performed using TruSeq
PE Cluster Kit v2.0, which was then followed by another 100 cycles.
Image analysis and base calling were performed using the standard
Illumina Pipeline consisting of Real time Analysis (RTA) version
v1.12.4.2 and Casava v1.8 with default settings.
GaHV-1 DNA sequence analysis
Pyrosequencing data was assembled from reads using GS De
Novo Assembler (Roche, Indianapolis, IN), Sequencher (Gene
Codes, Ann Arbor, MI) and the MIRA assembler v3.2.1 (Chevreux
et al., 1999). Regions containing mononucleotide reiterations 46,
ambiguities and gaps in the deep-sequencing data were resolved
through Illumina re-sequencing and reassembly using MIRA. The
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passage progenies therefore represent hybrid assembly from two
sequencing technologies. After assembly of each sample, reads
were re-mapped to the consensus sequence using BWA (http://dx.
doi.org/10.1093/bioinformatics/btp324). A pileup ﬁle containing
sequencing depth data was generated from the resulting SAM ﬁle
using samtools (http://dx.doi.org/10.1093/bioinformatics/btp352).
This ﬁle was parsed to generate base frequencies at each position
in the alignment, ignoring individual read positions with base
qualo10 on the phred scale. Multiple sequence alignments of all
eight genomes were generated using MAFFT (Katoh et al., 2005) in
order identify SNPs at the consensus level. Only these consensus
SNPs were evaluated at the read depth level. Each SNP position was
examined and ‘‘positions of interest’’ were determined where, for
any of the samples, two or more bases each made upZ2% of the
total depth (qualZ10). In other words, at least one sample had
a minority populationZ2%. In determining both quality and
frequency cutoffs we took into consideration the typical Illumina
error rate, which is generally found to be o1% across reads.
In order to identify single nucleotide polymorphisms, synon-
ymous and non-synonymous substitutions and insertions/
deletion (indels) newly sequenced genomes were compared to
all non-composite GaHV-1 genomic sequences in GenBank
(81658-JN542535, 1874C5-JN542533, 63140/C/08/BR-JN542536,
USDA-JN542534, SA2-JN596962, A20-JN596963, Laryngo-Vacs-
JQ083494, LT Blens–JQ083493, Serva-HQ630064, ACC78-
JN804826 and CL9-JN804827 using multiple sequence alignments
MAFFT (Katoh et al., 2005) and the Mega4 programs (Kumar et al.,
2004). Short nucleotide alignments were performed using Multa-
lin (Corpet, 1988). All genomic sequences were maintained and
analyzed using Lasergene (DNASTAR, Madison, WI), NCBI Entrez,
and other web-based tools. Homology searches were conducted
using the NCBI program BLAST with default settings.Appendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2013.02.007.References
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